EA201491026A1 - Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 - Google Patents

Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1

Info

Publication number
EA201491026A1
EA201491026A1 EA201491026A EA201491026A EA201491026A1 EA 201491026 A1 EA201491026 A1 EA 201491026A1 EA 201491026 A EA201491026 A EA 201491026A EA 201491026 A EA201491026 A EA 201491026A EA 201491026 A1 EA201491026 A1 EA 201491026A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
derivatives
parp
adp
ribose
Prior art date
Application number
EA201491026A
Other languages
English (en)
Other versions
EA027800B1 (ru
Inventor
Джанлука Мариано Энрико Папео
Алессандра Чирла
Маттео Д'Анелло
Алессандра Сколаро
Фабио Дзуккотто
Original Assignee
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. filed Critical НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Publication of EA201491026A1 publication Critical patent/EA201491026A1/ru
Publication of EA027800B1 publication Critical patent/EA027800B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены замещенные производные 3-фенилизохинолин-1(2Н)-она, которые селективно ингибируют активность поли(АДФ-рибоза)полимеразы PARP-1 в отношении поли(АДФ-рибоза)полимеразы PARP-2. Поэтому соединения по настоящему изобретению полезны при лечении заболеваний, таких как злокачественная опухоль, сердечно-сосудистые заболевания, поражение центральной нервной системы и различные формы воспаления. В изобретении предложены также способы получения этих соединений, фармацевтические композиции, содержащие эти соединения, и способы лечения заболеваний с применением фармацевтических композиций, содержащих эти соединения.
EA201491026A 2011-11-25 2012-11-20 Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 EA027800B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190687 2011-11-25
EP12161489 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors

Publications (2)

Publication Number Publication Date
EA201491026A1 true EA201491026A1 (ru) 2014-11-28
EA027800B1 EA027800B1 (ru) 2017-09-29

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491026A EA027800B1 (ru) 2011-11-25 2012-11-20 Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1

Country Status (15)

Country Link
US (1) US9422243B2 (ru)
EP (1) EP2788328B1 (ru)
JP (1) JP6106182B2 (ru)
KR (1) KR20140097457A (ru)
CN (1) CN103946214B (ru)
AU (1) AU2012342562B2 (ru)
BR (1) BR112014012031A2 (ru)
CA (1) CA2856759A1 (ru)
CL (1) CL2014001323A1 (ru)
EA (1) EA027800B1 (ru)
ES (1) ES2676068T3 (ru)
HK (1) HK1200166A1 (ru)
IN (1) IN2014CN04671A (ru)
MX (1) MX2014006015A (ru)
WO (1) WO2013076090A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013229229B2 (en) 2012-03-07 2017-10-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
NO3044221T3 (ru) * 2013-09-11 2018-07-21
CN105917007A (zh) * 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
BR112018008630A2 (pt) 2015-11-06 2018-10-30 Neurocrine Biosciences Inc derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528376A (ja) * 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AU2003255149A1 (en) * 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
EP2254888B1 (en) * 2008-02-22 2014-12-24 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物

Also Published As

Publication number Publication date
EP2788328B1 (en) 2018-01-31
ES2676068T3 (es) 2018-07-16
AU2012342562B2 (en) 2017-02-23
WO2013076090A1 (en) 2013-05-30
CL2014001323A1 (es) 2014-09-05
HK1200166A1 (en) 2015-07-31
CA2856759A1 (en) 2013-05-30
EA027800B1 (ru) 2017-09-29
JP6106182B2 (ja) 2017-03-29
CN103946214A (zh) 2014-07-23
AU2012342562A1 (en) 2014-07-10
JP2014533709A (ja) 2014-12-15
IN2014CN04671A (ru) 2015-09-18
US9422243B2 (en) 2016-08-23
CN103946214B (zh) 2016-08-17
BR112014012031A2 (pt) 2017-05-30
US20140336192A1 (en) 2014-11-13
KR20140097457A (ko) 2014-08-06
MX2014006015A (es) 2014-06-04
EP2788328A1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
NZ700928A (en) Dna-pk inhibitors
EA201401212A1 (ru) Производные пирролотриазинона
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
UA112795C2 (uk) Біциклічні піразинонові похідні
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201590820A1 (ru) Производные 4-карбоксамидоизоиндолинона в качестве селективных ингибиторов parp-1
EA201400707A1 (ru) Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MX362939B (es) Derivados de (aza-)isoquinolinona.
WO2010147898A3 (en) Small molecule inhibitors of spleen tyrosine kinase (syk)
EA201171448A1 (ru) Производные изохинолин-1(2h)-она в качестве ингибиторов parp-1
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
NZ630170A (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
WO2011006794A8 (en) 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
EA201491026A1 (ru) Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ